Phase I trial of a 72-h oxymorphone transdermal patch for moderate-to-severe chronic pain.
Latest Information Update: 08 Sep 2013
At a glance
- Drugs Oxymorphone (Primary)
- Indications Pain
- Focus Adverse reactions; Pharmacokinetics
- 03 Sep 2013 Results will be presented at 2013 PAINWeek according to a Phosphagenics media release.
- 25 Mar 2013 Primary safety endpoints have been met, according to a Phosphagenics media release.
- 25 Mar 2013 Status changed to completed, according to a Phosphagenics media release.